世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 生物学的ワクチン用アジュバント - 世界市場シェアとランキング、全体売上高と需要予測 2025-2031Biological Vaccines Adjuvants - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 生物学的ワクチンのアジュバントの世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されている。 アジュバント... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー生物学的ワクチンのアジュバントの世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されている。アジュバントとは、ワクチンの一部として配合され、感染に対する防御を誘導する能力を高める物質である。アジュバントは、免疫賦活能力が不十分な高度に精製された抗原の免疫原性を高めるためにワクチンに添加される物質であり、90年以上にわたってヒトのワクチンに使用されてきた。 世界の医薬品市場は、2022年には1,475億米ドルとなり、今後6年間のCAGRは5％で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行は、ワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。 本レポートは、生物学的ワクチンアジュバントの世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の生物学的ワクチンアジュバントの分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングに焦点を当てています。 生物学的ワクチン用アジュバントの市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データとともに、販売数量（K単位）と販売収益（百万ドル）で提供されます。定量分析および定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、生物学的ワクチン用アジュバントに関する十分な情報に基づいたビジネス上の意思決定を行えるよう支援します。 市場区分 企業別 GSK ダイナバックス・テクノロジーズ ノババックス アジェナス クロダ・インターナショナル セピック OZバイオサイエンス フィブロ・アニマルヘルス・コーポレーション アソシエイテッド・ブリティッシュ・フーズ インビボジェン メルクKGaA CSLリミテッド バーテルス アレルギー治療薬 リボックスGmbH カプティバット・ファーマシューティカルズ ユーロバイオロジクス パシフィック・ジーンテック ハワイバイオテクノロジー バクシン社 クリエイティブ・ダイアグノスティックス ライトバックスBV ムクタ・インダストリーズ オンコビル タイターマックスUSA タイプ別セグメント アルミニウムアジュバント エマルジョンアジュバント その他 用途別セグメント ヒト用ワクチン 動物用ワクチン 地域別 北米 アメリカ カナダ アジア太平洋 中国 日本 韓国 東南アジア インド オーストラリア その他のアジア太平洋地域 ヨーロッパ ドイツ フランス 英国 イタリア オランダ 北欧諸国 その他のヨーロッパ ラテンアメリカ メキシコ ブラジル その他のラテンアメリカ 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 その他のMEA 各章の概要 第1章： レポートの対象範囲、世界の総市場規模（金額、数量、価格）を紹介します。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章 生物学的ワクチン用アジュバントメーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章：タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展の可能性をカバーし、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。 第4章：用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章： 生物学的ワクチン用アジュバントの地域レベルでの売上、収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章 生物学的ワクチン用アジュバントの国別売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロファイルを提供し、製品の売上高、収益、価格、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Biological Vaccines Adjuvants Product Introduction 1.2 Global Biological Vaccines Adjuvants Market Size Forecast 1.2.1 Global Biological Vaccines Adjuvants Sales Value (2020-2031) 1.2.2 Global Biological Vaccines Adjuvants Sales Volume (2020-2031) 1.2.3 Global Biological Vaccines Adjuvants Sales Price (2020-2031) 1.3 Biological Vaccines Adjuvants Market Trends & Drivers 1.3.1 Biological Vaccines Adjuvants Industry Trends 1.3.2 Biological Vaccines Adjuvants Market Drivers & Opportunity 1.3.3 Biological Vaccines Adjuvants Market Challenges 1.3.4 Biological Vaccines Adjuvants Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Biological Vaccines Adjuvants Players Revenue Ranking (2024) 2.2 Global Biological Vaccines Adjuvants Revenue by Company (2020-2025) 2.3 Global Biological Vaccines Adjuvants Players Sales Volume Ranking (2024) 2.4 Global Biological Vaccines Adjuvants Sales Volume by Company Players (2020-2025) 2.5 Global Biological Vaccines Adjuvants Average Price by Company (2020-2025) 2.6 Key Manufacturers Biological Vaccines Adjuvants Manufacturing Base and Headquarters 2.7 Key Manufacturers Biological Vaccines Adjuvants Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Biological Vaccines Adjuvants 2.9 Biological Vaccines Adjuvants Market Competitive Analysis 2.9.1 Biological Vaccines Adjuvants Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Biological Vaccines Adjuvants Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Vaccines Adjuvants as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Aluminum Adjuvant 3.1.2 Emulsions Adjuvant 3.1.3 Others 3.2 Global Biological Vaccines Adjuvants Sales Value by Type 3.2.1 Global Biological Vaccines Adjuvants Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Biological Vaccines Adjuvants Sales Value, by Type (2020-2031) 3.2.3 Global Biological Vaccines Adjuvants Sales Value, by Type (%) (2020-2031) 3.3 Global Biological Vaccines Adjuvants Sales Volume by Type 3.3.1 Global Biological Vaccines Adjuvants Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Biological Vaccines Adjuvants Sales Volume, by Type (2020-2031) 3.3.3 Global Biological Vaccines Adjuvants Sales Volume, by Type (%) (2020-2031) 3.4 Global Biological Vaccines Adjuvants Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Human Vaccine 4.1.2 Veterinary Vaccine 4.2 Global Biological Vaccines Adjuvants Sales Value by Application 4.2.1 Global Biological Vaccines Adjuvants Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Biological Vaccines Adjuvants Sales Value, by Application (2020-2031) 4.2.3 Global Biological Vaccines Adjuvants Sales Value, by Application (%) (2020-2031) 4.3 Global Biological Vaccines Adjuvants Sales Volume by Application 4.3.1 Global Biological Vaccines Adjuvants Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Biological Vaccines Adjuvants Sales Volume, by Application (2020-2031) 4.3.3 Global Biological Vaccines Adjuvants Sales Volume, by Application (%) (2020-2031) 4.4 Global Biological Vaccines Adjuvants Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Biological Vaccines Adjuvants Sales Value by Region 5.1.1 Global Biological Vaccines Adjuvants Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Biological Vaccines Adjuvants Sales Value by Region (2020-2025) 5.1.3 Global Biological Vaccines Adjuvants Sales Value by Region (2026-2031) 5.1.4 Global Biological Vaccines Adjuvants Sales Value by Region (%), (2020-2031) 5.2 Global Biological Vaccines Adjuvants Sales Volume by Region 5.2.1 Global Biological Vaccines Adjuvants Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Biological Vaccines Adjuvants Sales Volume by Region (2020-2025) 5.2.3 Global Biological Vaccines Adjuvants Sales Volume by Region (2026-2031) 5.2.4 Global Biological Vaccines Adjuvants Sales Volume by Region (%), (2020-2031) 5.3 Global Biological Vaccines Adjuvants Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Biological Vaccines Adjuvants Sales Value, 2020-2031 5.4.2 North America Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Biological Vaccines Adjuvants Sales Value, 2020-2031 5.5.2 Europe Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Biological Vaccines Adjuvants Sales Value, 2020-2031 5.6.2 Asia Pacific Biological Vaccines Adjuvants Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Biological Vaccines Adjuvants Sales Value, 2020-2031 5.7.2 South America Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Biological Vaccines Adjuvants Sales Value, 2020-2031 5.8.2 Middle East & Africa Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Biological Vaccines Adjuvants Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Biological Vaccines Adjuvants Sales Value 6.2.1 Key Countries/Regions Biological Vaccines Adjuvants Sales Value, 2020-2031 6.2.2 Key Countries/Regions Biological Vaccines Adjuvants Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Biological Vaccines Adjuvants Sales Value, 2020-2031 6.3.2 United States Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Biological Vaccines Adjuvants Sales Value, 2020-2031 6.4.2 Europe Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Biological Vaccines Adjuvants Sales Value, 2020-2031 6.5.2 China Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.5.3 China Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Biological Vaccines Adjuvants Sales Value, 2020-2031 6.6.2 Japan Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Biological Vaccines Adjuvants Sales Value, 2020-2031 6.7.2 South Korea Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Biological Vaccines Adjuvants Sales Value, 2020-2031 6.8.2 Southeast Asia Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Biological Vaccines Adjuvants Sales Value, 2020-2031 6.9.2 India Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.9.3 India Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 GSK 7.1.1 GSK Company Information 7.1.2 GSK Introduction and Business Overview 7.1.3 GSK Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 GSK Biological Vaccines Adjuvants Product Offerings 7.1.5 GSK Recent Development 7.2 Dynavax Technologies 7.2.1 Dynavax Technologies Company Information 7.2.2 Dynavax Technologies Introduction and Business Overview 7.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Dynavax Technologies Biological Vaccines Adjuvants Product Offerings 7.2.5 Dynavax Technologies Recent Development 7.3 Novavax 7.3.1 Novavax Company Information 7.3.2 Novavax Introduction and Business Overview 7.3.3 Novavax Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Novavax Biological Vaccines Adjuvants Product Offerings 7.3.5 Novavax Recent Development 7.4 Agenus 7.4.1 Agenus Company Information 7.4.2 Agenus Introduction and Business Overview 7.4.3 Agenus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Agenus Biological Vaccines Adjuvants Product Offerings 7.4.5 Agenus Recent Development 7.5 Croda International 7.5.1 Croda International Company Information 7.5.2 Croda International Introduction and Business Overview 7.5.3 Croda International Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Croda International Biological Vaccines Adjuvants Product Offerings 7.5.5 Croda International Recent Development 7.6 Seppic 7.6.1 Seppic Company Information 7.6.2 Seppic Introduction and Business Overview 7.6.3 Seppic Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Seppic Biological Vaccines Adjuvants Product Offerings 7.6.5 Seppic Recent Development 7.7 OZ Biosciences 7.7.1 OZ Biosciences Company Information 7.7.2 OZ Biosciences Introduction and Business Overview 7.7.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 OZ Biosciences Biological Vaccines Adjuvants Product Offerings 7.7.5 OZ Biosciences Recent Development 7.8 Phibro Animal Health Corporation 7.8.1 Phibro Animal Health Corporation Company Information 7.8.2 Phibro Animal Health Corporation Introduction and Business Overview 7.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Offerings 7.8.5 Phibro Animal Health Corporation Recent Development 7.9 Associated British Foods 7.9.1 Associated British Foods Company Information 7.9.2 Associated British Foods Introduction and Business Overview 7.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Associated British Foods Biological Vaccines Adjuvants Product Offerings 7.9.5 Associated British Foods Recent Development 7.10 InvivoGen 7.10.1 InvivoGen Company Information 7.10.2 InvivoGen Introduction and Business Overview 7.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 InvivoGen Biological Vaccines Adjuvants Product Offerings 7.10.5 InvivoGen Recent Development 7.11 Merck KGaA 7.11.1 Merck KGaA Company Information 7.11.2 Merck KGaA Introduction and Business Overview 7.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Merck KGaA Biological Vaccines Adjuvants Product Offerings 7.11.5 Merck KGaA Recent Development 7.12 CSL Limited 7.12.1 CSL Limited Company Information 7.12.2 CSL Limited Introduction and Business Overview 7.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 CSL Limited Biological Vaccines Adjuvants Product Offerings 7.12.5 CSL Limited Recent Development 7.13 Vertellus 7.13.1 Vertellus Company Information 7.13.2 Vertellus Introduction and Business Overview 7.13.3 Vertellus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.13.4 Vertellus Biological Vaccines Adjuvants Product Offerings 7.13.5 Vertellus Recent Development 7.14 Allergy Therapeutics 7.14.1 Allergy Therapeutics Company Information 7.14.2 Allergy Therapeutics Introduction and Business Overview 7.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.14.4 Allergy Therapeutics Biological Vaccines Adjuvants Product Offerings 7.14.5 Allergy Therapeutics Recent Development 7.15 Riboxx GmbH 7.15.1 Riboxx GmbH Company Information 7.15.2 Riboxx GmbH Introduction and Business Overview 7.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.15.4 Riboxx GmbH Biological Vaccines Adjuvants Product Offerings 7.15.5 Riboxx GmbH Recent Development 7.16 CaPtivatϵ Pharmaceuticals 7.16.1 CaPtivatϵ Pharmaceuticals Company Information 7.16.2 CaPtivatϵ Pharmaceuticals Introduction and Business Overview 7.16.3 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.16.4 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product Offerings 7.16.5 CaPtivatϵ Pharmaceuticals Recent Development 7.17 EuBiologics 7.17.1 EuBiologics Company Information 7.17.2 EuBiologics Introduction and Business Overview 7.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.17.4 EuBiologics Biological Vaccines Adjuvants Product Offerings 7.17.5 EuBiologics Recent Development 7.18 Pacific GeneTech 7.18.1 Pacific GeneTech Company Information 7.18.2 Pacific GeneTech Introduction and Business Overview 7.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.18.4 Pacific GeneTech Biological Vaccines Adjuvants Product Offerings 7.18.5 Pacific GeneTech Recent Development 7.19 Hawaii Biotech 7.19.1 Hawaii Biotech Company Information 7.19.2 Hawaii Biotech Introduction and Business Overview 7.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.19.4 Hawaii Biotech Biological Vaccines Adjuvants Product Offerings 7.19.5 Hawaii Biotech Recent Development 7.20 Vaxine Pty Ltd. 7.20.1 Vaxine Pty Ltd. Company Information 7.20.2 Vaxine Pty Ltd. Introduction and Business Overview 7.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.20.4 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Offerings 7.20.5 Vaxine Pty Ltd. Recent Development 7.21 Creative Diagnostics 7.21.1 Creative Diagnostics Company Information 7.21.2 Creative Diagnostics Introduction and Business Overview 7.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.21.4 Creative Diagnostics Biological Vaccines Adjuvants Product Offerings 7.21.5 Creative Diagnostics Recent Development 7.22 LiteVax BV 7.22.1 LiteVax BV Company Information 7.22.2 LiteVax BV Introduction and Business Overview 7.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.22.4 LiteVax BV Biological Vaccines Adjuvants Product Offerings 7.22.5 LiteVax BV Recent Development 7.23 Mukta Industries 7.23.1 Mukta Industries Company Information 7.23.2 Mukta Industries Introduction and Business Overview 7.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.23.4 Mukta Industries Biological Vaccines Adjuvants Product Offerings 7.23.5 Mukta Industries Recent Development 7.24 Oncovir 7.24.1 Oncovir Company Information 7.24.2 Oncovir Introduction and Business Overview 7.24.3 Oncovir Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.24.4 Oncovir Biological Vaccines Adjuvants Product Offerings 7.24.5 Oncovir Recent Development 7.25 TiterMax USA 7.25.1 TiterMax USA Company Information 7.25.2 TiterMax USA Introduction and Business Overview 7.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.25.4 TiterMax USA Biological Vaccines Adjuvants Product Offerings 7.25.5 TiterMax USA Recent Development 8 Industry Chain Analysis 8.1 Biological Vaccines Adjuvants Industrial Chain 8.2 Biological Vaccines Adjuvants Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Biological Vaccines Adjuvants Sales Model 8.5.2 Sales Channel 8.5.3 Biological Vaccines Adjuvants Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Biological Vaccines Adjuvants was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031. Table of Contents1 Market Overview1.1 Biological Vaccines Adjuvants Product Introduction 1.2 Global Biological Vaccines Adjuvants Market Size Forecast 1.2.1 Global Biological Vaccines Adjuvants Sales Value (2020-2031) 1.2.2 Global Biological Vaccines Adjuvants Sales Volume (2020-2031) 1.2.3 Global Biological Vaccines Adjuvants Sales Price (2020-2031) 1.3 Biological Vaccines Adjuvants Market Trends & Drivers 1.3.1 Biological Vaccines Adjuvants Industry Trends 1.3.2 Biological Vaccines Adjuvants Market Drivers & Opportunity 1.3.3 Biological Vaccines Adjuvants Market Challenges 1.3.4 Biological Vaccines Adjuvants Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Biological Vaccines Adjuvants Players Revenue Ranking (2024) 2.2 Global Biological Vaccines Adjuvants Revenue by Company (2020-2025) 2.3 Global Biological Vaccines Adjuvants Players Sales Volume Ranking (2024) 2.4 Global Biological Vaccines Adjuvants Sales Volume by Company Players (2020-2025) 2.5 Global Biological Vaccines Adjuvants Average Price by Company (2020-2025) 2.6 Key Manufacturers Biological Vaccines Adjuvants Manufacturing Base and Headquarters 2.7 Key Manufacturers Biological Vaccines Adjuvants Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Biological Vaccines Adjuvants 2.9 Biological Vaccines Adjuvants Market Competitive Analysis 2.9.1 Biological Vaccines Adjuvants Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Biological Vaccines Adjuvants Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Vaccines Adjuvants as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Aluminum Adjuvant 3.1.2 Emulsions Adjuvant 3.1.3 Others 3.2 Global Biological Vaccines Adjuvants Sales Value by Type 3.2.1 Global Biological Vaccines Adjuvants Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Biological Vaccines Adjuvants Sales Value, by Type (2020-2031) 3.2.3 Global Biological Vaccines Adjuvants Sales Value, by Type (%) (2020-2031) 3.3 Global Biological Vaccines Adjuvants Sales Volume by Type 3.3.1 Global Biological Vaccines Adjuvants Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Biological Vaccines Adjuvants Sales Volume, by Type (2020-2031) 3.3.3 Global Biological Vaccines Adjuvants Sales Volume, by Type (%) (2020-2031) 3.4 Global Biological Vaccines Adjuvants Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Human Vaccine 4.1.2 Veterinary Vaccine 4.2 Global Biological Vaccines Adjuvants Sales Value by Application 4.2.1 Global Biological Vaccines Adjuvants Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Biological Vaccines Adjuvants Sales Value, by Application (2020-2031) 4.2.3 Global Biological Vaccines Adjuvants Sales Value, by Application (%) (2020-2031) 4.3 Global Biological Vaccines Adjuvants Sales Volume by Application 4.3.1 Global Biological Vaccines Adjuvants Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Biological Vaccines Adjuvants Sales Volume, by Application (2020-2031) 4.3.3 Global Biological Vaccines Adjuvants Sales Volume, by Application (%) (2020-2031) 4.4 Global Biological Vaccines Adjuvants Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Biological Vaccines Adjuvants Sales Value by Region 5.1.1 Global Biological Vaccines Adjuvants Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Biological Vaccines Adjuvants Sales Value by Region (2020-2025) 5.1.3 Global Biological Vaccines Adjuvants Sales Value by Region (2026-2031) 5.1.4 Global Biological Vaccines Adjuvants Sales Value by Region (%), (2020-2031) 5.2 Global Biological Vaccines Adjuvants Sales Volume by Region 5.2.1 Global Biological Vaccines Adjuvants Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Biological Vaccines Adjuvants Sales Volume by Region (2020-2025) 5.2.3 Global Biological Vaccines Adjuvants Sales Volume by Region (2026-2031) 5.2.4 Global Biological Vaccines Adjuvants Sales Volume by Region (%), (2020-2031) 5.3 Global Biological Vaccines Adjuvants Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Biological Vaccines Adjuvants Sales Value, 2020-2031 5.4.2 North America Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Biological Vaccines Adjuvants Sales Value, 2020-2031 5.5.2 Europe Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Biological Vaccines Adjuvants Sales Value, 2020-2031 5.6.2 Asia Pacific Biological Vaccines Adjuvants Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Biological Vaccines Adjuvants Sales Value, 2020-2031 5.7.2 South America Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Biological Vaccines Adjuvants Sales Value, 2020-2031 5.8.2 Middle East & Africa Biological Vaccines Adjuvants Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Biological Vaccines Adjuvants Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Biological Vaccines Adjuvants Sales Value 6.2.1 Key Countries/Regions Biological Vaccines Adjuvants Sales Value, 2020-2031 6.2.2 Key Countries/Regions Biological Vaccines Adjuvants Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Biological Vaccines Adjuvants Sales Value, 2020-2031 6.3.2 United States Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Biological Vaccines Adjuvants Sales Value, 2020-2031 6.4.2 Europe Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Biological Vaccines Adjuvants Sales Value, 2020-2031 6.5.2 China Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.5.3 China Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Biological Vaccines Adjuvants Sales Value, 2020-2031 6.6.2 Japan Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Biological Vaccines Adjuvants Sales Value, 2020-2031 6.7.2 South Korea Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Biological Vaccines Adjuvants Sales Value, 2020-2031 6.8.2 Southeast Asia Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Biological Vaccines Adjuvants Sales Value, 2020-2031 6.9.2 India Biological Vaccines Adjuvants Sales Value by Type (%), 2024 VS 2031 6.9.3 India Biological Vaccines Adjuvants Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 GSK 7.1.1 GSK Company Information 7.1.2 GSK Introduction and Business Overview 7.1.3 GSK Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 GSK Biological Vaccines Adjuvants Product Offerings 7.1.5 GSK Recent Development 7.2 Dynavax Technologies 7.2.1 Dynavax Technologies Company Information 7.2.2 Dynavax Technologies Introduction and Business Overview 7.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Dynavax Technologies Biological Vaccines Adjuvants Product Offerings 7.2.5 Dynavax Technologies Recent Development 7.3 Novavax 7.3.1 Novavax Company Information 7.3.2 Novavax Introduction and Business Overview 7.3.3 Novavax Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Novavax Biological Vaccines Adjuvants Product Offerings 7.3.5 Novavax Recent Development 7.4 Agenus 7.4.1 Agenus Company Information 7.4.2 Agenus Introduction and Business Overview 7.4.3 Agenus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Agenus Biological Vaccines Adjuvants Product Offerings 7.4.5 Agenus Recent Development 7.5 Croda International 7.5.1 Croda International Company Information 7.5.2 Croda International Introduction and Business Overview 7.5.3 Croda International Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Croda International Biological Vaccines Adjuvants Product Offerings 7.5.5 Croda International Recent Development 7.6 Seppic 7.6.1 Seppic Company Information 7.6.2 Seppic Introduction and Business Overview 7.6.3 Seppic Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Seppic Biological Vaccines Adjuvants Product Offerings 7.6.5 Seppic Recent Development 7.7 OZ Biosciences 7.7.1 OZ Biosciences Company Information 7.7.2 OZ Biosciences Introduction and Business Overview 7.7.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 OZ Biosciences Biological Vaccines Adjuvants Product Offerings 7.7.5 OZ Biosciences Recent Development 7.8 Phibro Animal Health Corporation 7.8.1 Phibro Animal Health Corporation Company Information 7.8.2 Phibro Animal Health Corporation Introduction and Business Overview 7.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Offerings 7.8.5 Phibro Animal Health Corporation Recent Development 7.9 Associated British Foods 7.9.1 Associated British Foods Company Information 7.9.2 Associated British Foods Introduction and Business Overview 7.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Associated British Foods Biological Vaccines Adjuvants Product Offerings 7.9.5 Associated British Foods Recent Development 7.10 InvivoGen 7.10.1 InvivoGen Company Information 7.10.2 InvivoGen Introduction and Business Overview 7.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 InvivoGen Biological Vaccines Adjuvants Product Offerings 7.10.5 InvivoGen Recent Development 7.11 Merck KGaA 7.11.1 Merck KGaA Company Information 7.11.2 Merck KGaA Introduction and Business Overview 7.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Merck KGaA Biological Vaccines Adjuvants Product Offerings 7.11.5 Merck KGaA Recent Development 7.12 CSL Limited 7.12.1 CSL Limited Company Information 7.12.2 CSL Limited Introduction and Business Overview 7.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 CSL Limited Biological Vaccines Adjuvants Product Offerings 7.12.5 CSL Limited Recent Development 7.13 Vertellus 7.13.1 Vertellus Company Information 7.13.2 Vertellus Introduction and Business Overview 7.13.3 Vertellus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.13.4 Vertellus Biological Vaccines Adjuvants Product Offerings 7.13.5 Vertellus Recent Development 7.14 Allergy Therapeutics 7.14.1 Allergy Therapeutics Company Information 7.14.2 Allergy Therapeutics Introduction and Business Overview 7.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.14.4 Allergy Therapeutics Biological Vaccines Adjuvants Product Offerings 7.14.5 Allergy Therapeutics Recent Development 7.15 Riboxx GmbH 7.15.1 Riboxx GmbH Company Information 7.15.2 Riboxx GmbH Introduction and Business Overview 7.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.15.4 Riboxx GmbH Biological Vaccines Adjuvants Product Offerings 7.15.5 Riboxx GmbH Recent Development 7.16 CaPtivatϵ Pharmaceuticals 7.16.1 CaPtivatϵ Pharmaceuticals Company Information 7.16.2 CaPtivatϵ Pharmaceuticals Introduction and Business Overview 7.16.3 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.16.4 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product Offerings 7.16.5 CaPtivatϵ Pharmaceuticals Recent Development 7.17 EuBiologics 7.17.1 EuBiologics Company Information 7.17.2 EuBiologics Introduction and Business Overview 7.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.17.4 EuBiologics Biological Vaccines Adjuvants Product Offerings 7.17.5 EuBiologics Recent Development 7.18 Pacific GeneTech 7.18.1 Pacific GeneTech Company Information 7.18.2 Pacific GeneTech Introduction and Business Overview 7.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.18.4 Pacific GeneTech Biological Vaccines Adjuvants Product Offerings 7.18.5 Pacific GeneTech Recent Development 7.19 Hawaii Biotech 7.19.1 Hawaii Biotech Company Information 7.19.2 Hawaii Biotech Introduction and Business Overview 7.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.19.4 Hawaii Biotech Biological Vaccines Adjuvants Product Offerings 7.19.5 Hawaii Biotech Recent Development 7.20 Vaxine Pty Ltd. 7.20.1 Vaxine Pty Ltd. Company Information 7.20.2 Vaxine Pty Ltd. Introduction and Business Overview 7.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.20.4 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Offerings 7.20.5 Vaxine Pty Ltd. Recent Development 7.21 Creative Diagnostics 7.21.1 Creative Diagnostics Company Information 7.21.2 Creative Diagnostics Introduction and Business Overview 7.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.21.4 Creative Diagnostics Biological Vaccines Adjuvants Product Offerings 7.21.5 Creative Diagnostics Recent Development 7.22 LiteVax BV 7.22.1 LiteVax BV Company Information 7.22.2 LiteVax BV Introduction and Business Overview 7.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.22.4 LiteVax BV Biological Vaccines Adjuvants Product Offerings 7.22.5 LiteVax BV Recent Development 7.23 Mukta Industries 7.23.1 Mukta Industries Company Information 7.23.2 Mukta Industries Introduction and Business Overview 7.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.23.4 Mukta Industries Biological Vaccines Adjuvants Product Offerings 7.23.5 Mukta Industries Recent Development 7.24 Oncovir 7.24.1 Oncovir Company Information 7.24.2 Oncovir Introduction and Business Overview 7.24.3 Oncovir Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.24.4 Oncovir Biological Vaccines Adjuvants Product Offerings 7.24.5 Oncovir Recent Development 7.25 TiterMax USA 7.25.1 TiterMax USA Company Information 7.25.2 TiterMax USA Introduction and Business Overview 7.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025) 7.25.4 TiterMax USA Biological Vaccines Adjuvants Product Offerings 7.25.5 TiterMax USA Recent Development 8 Industry Chain Analysis 8.1 Biological Vaccines Adjuvants Industrial Chain 8.2 Biological Vaccines Adjuvants Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Biological Vaccines Adjuvants Sales Model 8.5.2 Sales Channel 8.5.3 Biological Vaccines Adjuvants Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD（vaccines）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
